secwatch.observer — SEC 8-K summary
======================================

Issuer:     BAXTER INTERNATIONAL INC (BAX)
CIK:        0000010456
Form:       8-K
Filed at:   2025-02-03T23:59:59+00:00
Accession:  0001628280-25-003388
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Baxter completes $3.8B sale of kidney care business (Vantive) to Carlyle-backed buyers; net proceeds ~$3.71B
--------------------------------------------------------------------------------

- Sale closed Jan 31, 2025; net pre-tax cash proceeds of approximately $3.71B after working capital and debt adjustments.
- Chris Toth, EVP and Group President Kidney Care, ceased as executive officer effective closing date.
- Amendment to purchase agreement clarifies cash adjustment definitions, post-closing cash sweep mechanics, and excess withholding tax exposure.
- Original aggregate purchase price of $3.80B in cash, subject to closing adjustments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10456/000162828025003388/0001628280-25-003388-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10456/000162828025003388/bax-20250131.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-003388

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer